Thylakoids reduce body fat and fat cell size by binding to dietary fat making it less available for absorption in high-fat fed mice by Karin G. Stenkula et al.
RESEARCH Open Access
Thylakoids reduce body fat and fat cell size
by binding to dietary fat making it less
available for absorption in high-fat fed
mice
Karin G. Stenkula1*, Eva-Lena Stenblom2, Caroline Montelius2, Emil Egecioglu2 and Charlotte Erlanson-Albertsson2
Abstract
Background: Dietary thylakoids derived from spinach have beneficial effects on body fat accumulation and blood
lipids as demonstrated in humans and rodents. Important mechanisms established include delayed fat digestion in
the intestine, without causing steatorrhea, and increased fatty acid oxidation in intestinal cells. The objective of our
study was to elucidate if increased fecal fat excretion is an important mechanism to normalize adipose tissue
metabolism during high-fat feeding in mice supplemented with thylakoids.
Methods: Mice were randomized to receive HFD or thylHFD for 14 days (n = 14 for the control group and 16 for
the thylakoid group). The effect of thylakoids on body fat distribution, faecal and liver fat content, and adipose
tissue metabolism was investigated following high-fat feeding.
Results: Thylakoid supplementation for 14 days caused an increased faecal fat content without compensatory
eating compared to control. As a result, thylakoid treated animals had reduced fat mass depots and reduced liver
fat accumulation compared to control. The size distribution of adipocytes isolated from visceral adipose tissue was
narrowed and the cell size decreased. Adipocytes isolated from thylakoid-treated mice displayed a significantly
increased lipogenesis, and protein expression of peroxisome proliferator-activated receptor gamma (PPARγ),
down-stream target FAS, as well as transcription factor coactivators PGC1-α and LPIN-1 were upregulated in
adipose tissue from thylakoid-fed mice.
Conclusions: Together, these data suggest that thylakoid supplementation reduces body fat and fat cell size by
binding to dietary fat and increasing its fecal excretion, thus reducing dietary fat available for absorption.
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Background
Obesity is characterized by an excess fat mass due to
chronic imbalance between energy intake and energy ex-
penditure. Several comorbidities are associated with
obesity, such as diabetes, cardiovascular disease and
non-alcoholic fatty-liver disease (NAFLD). These comor-
bidities increase in prevalence at a high rate, under-
scoring an urgent need for strategies to prevent the
emerging global epidemic [1].
An overload of energy in the form of dietary fat plays
a significant role in promoting obesity compared to pro-
tein and carbohydrate [2]. Weight loss can therefore be
achieved by reducing the consumption of fat or the ab-
sorption of fat. Lipase inhibitors are efficient in reducing
body weight, however often with apparent gastrointes-
tinal side effects such as steatorrhea [3].
Thylakoids are biological membranes, derived from
green plants, that reversibly inhibit pancreatic lipase by
binding to dietary fat droplets during fat digestion,
thereby preventing access of the lipolytic enzymes
present in the gastrointestinal tract [4]. In rodents long-
term supplementation with thylakoids in high-fat diet
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(HFD) resulted in decreased body weight, decreased fat
mass and decreased food intake [5]. It was not clear
whether the reduction in food intake seen in these stud-
ies was in itself sufficient to explain the observed loss of
fat mass [6]. There might also be a reduced fat absorp-
tion or an increased fatty acid oxidation. We however
found no sign of steatorrhea in spite of a body weight
loss, neither in rodent studies [7] nor in human studies
[8, 9]. We also observed an increased expression of fat
oxidative enzymes in the gut and an increased fat oxida-
tion in rat fed high-fat diet with thylakoid supplementa-
tion [10], suggesting other mechanisms to explain the fat
mass reduction. This could be fecal fat excretion and/or
a recruitment of new adipocytes that have a more active
metabolism. When storing energy, adipocytes initially
grow in size, followed by differentiation and recruitment
of new adipocytes [11, 12]. Special genes have been iden-
tified, the PPAR genes, which when activated increase
the number of adipocytes so as to direct the energy to
small adipocytes, which are less inflammatory [13].
In the present study we were interested in understand-
ing the mechanism of action for a reduction of fat mass
at the adipose cell level following thylakoid supplemen-
tation, by focusing on metabolism and cell size distribu-
tion of adipocytes [14]. We were also interested to find
out if there was a fecal fat excretion that was not a full
scale steatorrhea. To that end, mice were fed high-fat
diet for two weeks and the adipocyte metabolism investi-
gated as well as fecal fat excretion.
Methods
Animals
Ten to twelve week-old male C57Bl6 mice (Taconic,
Denmark) weighing approximately 24–26 g upon arrival
were used in the study. The animals were housed in
rooms maintained on a 12/12-h light/dark cycle with
lights on at 07:00 under stable conditions. The mice had
ad libitum access to standard chow (R3, Lantmännen,
Vadstena, Sweden) and tap water until the start of the
experiments.
Material
PPARγ, LPIN-1, FAS and PGC-1α antibodies were from
Cell Signal Technology (Denvers, USA), β-actin antibody
was from Sigma (Stockholm, Sweden).
Thylakoids and diets
The chlorophyll-containing green-plant thylakoids used
in the study were prepared from spinach leaves, as previ-
ously described [15], followed by drum drying. 100 g of
thylakoids contain 23.5 g protein, 11.9 g fat, 41.7 g
carbohydrate, 0.27 g sodium, 2.0 g chlorophyll, 27.9 mg
lutein, 0.7 mg zeaxanthine, 4.8 mg beta-carotene,
0.021 mg vitamin A, 1.3 mg vitamin K, 6.0 mg vitamin E
and 0.17 mg folic acid.
A high fat diet (HFD) and an isocaloric thylakoid-
enriched HFD (thylHFD) were used in the experiments.
The diets were designed to have the same macronutrient
composition and the energy distribution of 46 E% fat, 18
E% protein and 36 E% carbohydrates. The diets were based
on the D12451 high fat diet from Research Diets (Research
Diets®, New Brunswick, NJ, USA). The thylHFD contained
33% w/w thylakoid extract (Appethyl®, Greenleaf Medical
AB, Stockholm, Sweden), which is comparable to previous
studies in rat that demonstrated effects on body weight
and food intake [5–7].
Experimental procedure
Upon arrival to the animal facility the mice were group
housed two and two and were acclimatised to the facil-
ities for a minimum of 7 days prior to the start of exper-
iments. The mice were randomized based on body
weight to receive HFD or thylHFD for 14 days (n = 14
for the control group and 16 for the thylakoid group).
New food was administered twice a week and food con-
sumption monitored. Body weight was measured day 0
(baseline), day 7 and at the end of the study on day 14.
The mice were then euthanized and liver and body fat
pads dissected and weighed and biopsies of adipose tis-
sue taken for in vitro analysis of primary adipocytes.
Dual-energy X-ray absorptiometry (DEXA)
To measure total body composition (total lean mass and
fat mass), DEXA was performed on a subset of the ani-
mals (n = 6 and 9 for HFD and thylHFD fed groups re-
spectively) using the Lunar PIXImus2™ DEXA scan (GE
Healthcare, WI, USA).
Faecal fat content
Faecal samples were collected from the mice (n = 14
(control) and 16 (thylakoid)) during the last 8 days of
the two-week period and dried for later analysis. The
faecal samples were analyzed for fat content using acid
hydrolysis (Eurofins Food & Feed testing laboratory,
Linköping, Sweden).
Liver triacylglycerol (TG) assay
Snap-frozen liver tissues were homogenized 1:4 in 50 mM
Tris–HCl pH 7.5, 1 mM EGTA, 1 mM EDTA, 0.27 M su-
crose, 5% NP-40, 1 mM dithiothreitol (DTT) and
complete protease and phosphatase inhibitor. Samples
were submitted to a cycle of heating (85 °C for 5 min,
room temperature for 10 min, and 85 °C for 5 min) and
centrifugation at 16000 xg for 2 min. The supernatant was
assayed using Infinity TG Liquide Stable Reagent (Thermo
Scientific, USA).
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Cell size distribution
Adipose cell-size distribution was measured using a
Beckman-Coulter counter after osmium fixation as de-
scribed previously [14, 16]. In brief, 10–20 mg of epi-
didymal adipose tissue sample (n = 6 samples/group)
were fixed in 1% osmium for 48 h, followed by washing
with NaCl. Adipose cell size was determined by a Beckman
Coulter Multisizer III with a 400 μm aperture. The instru-
ment was set to count 6,000 particles, and the fixed-cell
suspension was diluted so that coincident counting was
<10%. After collection of pulse sizes, the data were
expressed as particle diameters and displayed as histograms
of counts against diameter using linear bins and a linear
scale for the x-axis.
Adipose cell isolation and lipogenesis assay
To measure lipogenesis, primary mouse adipocytes were
isolated from epididymal and mesenteric fat tissue as de-
scribed previously [17]. Lipogenesis was measured ac-
cording to a previous method [18]. In brief, adipocytes
were re-suspended in Krebs-Ringer (KRH) medium con-
taining 25 mM Hepes pH 7.4, 200 nM adenosine,
0.55 mM glucose and 3.5% BSA (w/v). In triplicates,
700 μl of the 2%(v/v) adipocyte cell suspension was
added to each tube and incubated for 1-h at 37 °C with
14 μl of 22 μCi/ml tritiated glucose (D-[6-3H]-glucose,
Perkin Elmer, Cambridge, UK) either with or without 28
nM insulin. After the incubation, the assay was stopped
by adding 3.5 ml of 2,5-diphenyloxazole (Sigma-Aldrich,
Stockholm, Sweden) and 1,4-bis (5-phenloxazol-2-yl) ben-
zene (Sigma) toluene-based scintillation liquid (Sigma). A
zero sample was also included in the experiment to meas-
ure how much glucose ends up in the lipid phase during
extraction without having been used for lipid synthesis.
This was done by adding 700 μl of the 2% adipocyte cell
suspension to scintillation tubes containing 14 μl of
22 μCi/ml tritiated glucose which was then stopped im-
mediately by adding 3.5 ml PPO-POPOP toluene-based
scintillation liquid.
Western blot
Intact adipose tissue was homogenized with a polytron
(Omni International TH) in lysis buffer containing 50 mM
Tris/HCl pH 7.5, 1 mM EGTA, 1 mM EDTA, 1 mM so-
dium orthovanadate, 10 mM sodium-β-glycerophosphate,
50 mM sodium fluoride, 5 mM sodium pyrophosphate,
0.27 M sucrose, 1% NP-40, 1 mM dithiothreitol (DTT)
and complete protease inhibitor cocktail (one tablet/
50 ml) (lysis buffer). Lysates were centrifuged for 15 min
at 10000 × g and protein concentrations were determined
by Bradford [19]. Adipose tissue lysates were heated at
95 °C for 2 min in SDS sample buffer, and subjected to
polyacrylamide gel electrophoresis on pre-cast BioRad
gradient gels and electro transfer to nitrocellulose
membrane. An amount of ten μg protein was loaded per
sample according to Bradford protein quantification.
Membranes were blocked for 30 min in 50 mM Tris/HCl
pH 7.6, 137 mM NaCl and 0.1% (w/v) Tween-20 (TBS-T)
containing 10% (w/v) milk powder. The membranes were
then probed with indicated antibodies in TBS-T contain-
ing 5% (w/v) milk or 5% (w/v) BSA, for 16 h at 4 °C.
Detection was performed using horseradish peroxidase
conjugated secondary antibodies and the chemilumines-
cence reagent. The signal was visualized using a BioRad
Image camera and band intensities quantified using
BioRad Imaging software (Biorad, CA, USA).
Statistical analyses
Statistical analyses were done using Prism GraphPad
version 6 (GraphPad Software Inc. La Jolla, CA, USA).
Not assuming Gaussian distribution, Kruskal-Wallis stat-
istic and unpaired Mann–Whitney tests was used to de-
termine statistical differences. All data are presented as
median and interquartile range if not otherwise mentioned.
P-values < 0.05 were considered to be statistically different.
Results
Body weight gain and food intake
To examine the effect of thylakoids on body weight and
fat mass, mice were fed HFD or thylHFD for two weeks.
As expected, mice in both groups displayed significant
(p < 0.0001) body weight gain, which however was sup-
pressed in mice fed thylHFD compared to HFD mice at
the end of the study (p < 0.0001, Fig. .1a and b). A differ-
ence in body weight was noted already after one week
(p < 0.001) and continued during the second week of
feeding (Fig. .1a and b). Mice fed the thylHFD
showed reduced caloric intake compared to HFD-fed
mice (p < 0.05, Table I).
Body fat
After two weeks on HFD, DEXA-analysis revealed a re-
duced fat mass by 33% in the thylHFD-fed mice com-
pared to mice fed HFD (p < 0.01) (Fig. 2a). There was no
difference in lean mass (data not shown). Analysis of in-
dividual fat depots demonstrated a reduction in epididy-
mal fat (p < 0.0001, Fig. 2b), mesenteric fat (p < 0.0001,
Fig. 2c), retroperitoneal fat (p < 0.0001, Fig. 2d), inguinal
fat (p < 0.0001, Fig. 2e) and BAT (p < 0.0001, Fig. 2f ) in
thylHFD-fed mice compared to HFD.
Faeces analysis
Analysis of fat in the faeces demonstrated that the mice
receiving thylakoids had significantly higher lipid elimin-
ation through the faeces than high-fat fed control ani-
mals (Table 1), the fat content being 23 mg per day in
the thylakoids-fed animals and 10 mg per day in the
controls.
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Liver fat content
Livers from mice fed thylHFD had decreased fat (TG)
accumulation compared to the HFD-fed mice (p < 0.001,
Fig. 3). There was no difference in liver weight between
thylHFD-fed mice and HFD (p = 0.185, data not shown).
Lipid metabolism in adipocytes
Lipogenesis was measured using the incorporation of
tracer glucose into the triglycerides. In the non-
stimulated state, lipogenesis was increased both in cell-
isolates from mescenteric (p < 0.05) and epididymal fat
Fig. 2 a-f Measurements of body fat accumulation after two weeks in mice fed HFD vs. ThylHFD. Total body fat (%of BW measured by DEXA, a),
Epididymal fat b, Mesenteric fat c, Retroperitoneal fat d, Inguinal fat e and Brown adipose tissue f. Bars represent median and interquartile range.













































Body weight, 2 weeksa b
***
****
Fig.1 a-b Body weight development a and body weight gain b during the two-week study. Bars represent median and interquartile range.
Statistical difference of p < 0.05 was considered significant (*** = p < 0.001, **** = p < 0.0001)
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(p < 0.01) from the thylHFD mice compared with HFD-
fed mice (Fig. 4a). Insulin-stimulated lipogenesis was
similar in cells isolated from thylHFD-fed and HFD-fed
mice comparing both fat depots (Fig. 4b).
Cell size of adipocytes
In both groups, there was a bimodal cell distribution,
with a fraction of so-called small cells defined by the
nadir [16], the lowest point between the two distribu-
tions (indicated with an arrow in Fig. 5a), and a cell
population of larger cells, so-called large cells, to the
right of the nadir. In the HFD group, the large cells were
varying in size between 50–150 μm diameter, with a
mean cell size of 90 μm (Fig. 5b). In the thylakoid
treated animals, the cell size distribution was markedly
shifted to the left and more narrowed, with large cells
varying between 30–100 μm, with a decreased mean cell
size (~83 μm) (Fig. 5b). Overall, the cell size distribution
of thylHFD fed mice was comparable with the distribu-
tion curve from chow-fed mice, reported previously [12]
(Fig. 5a).
PPARγ, PGC-1α, LPIN-1 and FAS expression in epididymal
fat tissue
Quantification of Western blot analysis demonstrated
that thylakoid supplementation increased the protein ex-
pression of transcription factor PPARγ (Fig. 6a),
transcription factor coregulatory elements PGC-1α
(Fig. 6b), LPIN-1 (Fig. 6c), and down-stream target FAS
(Fig. 6d). Western blotting data used for quantification
(Fig. 6e). Protein expression was normalized to expres-
sion of β-actin.
Discussion
In this work we have demonstrated that green-plant thy-
lakoids protect against body fat accumulation due to
Table 1 Impact of high-fat diet with or without thylakoids on food intake and lipid excretion
Control HFD diet Thylakoid HFD
Food intake (g/day) 3.60 (3.52–3.84) 3.72 (3.44–3.87)
Caloric intake (kcal/day) 16.76 (16.41–17.91) 16.05 (14.88–16.71)a
Total lipid content in feces (mg/day) 9.60 (8.69–10.42) 22.73 (19.25–25.37)b


















Fig. 3 Liver fat accumulation in high-fat fed control and high-fat fed
thylakoid animals (mg triacylglycerides (TG)/mg tissue). Statistical
difference of p < 0.05 was considered significant (**p < 0.01)
Fig. 4 a-b Lipogenesis in the basal (non-stimulated) a and insulin-
stimulated (28 nM) b states in epididymal and mesenteric adipocytes
from mice fed HFD vs ThylHFD for two weeks. Bars represent median
and interquartile range. Statistical difference of p < 0.05 was considered
significant (*p < 0.05, **p < 0.01)
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high-fat feeding in mice. As a novel finding, an increased
faecal fat excretion was observed in the thylakoid-fed an-
imals, amounting to 23 mg per day in comparison to
10 mg in the control group. This is the first time green-
plant thylakoids were found to enhance fecal excretion
of fat and energy, which thus substantiates the well-
known finding of thylakoids as potent inhibitors of pan-
creatic lipase activity by binding to dietary lipids [5].
There was thus a substantial amount of fat in the faeces,
without reaching the levels of steatorrhea, defined as a
minimal fecal fat excretion of 35 mg per day in mouse
[20]. The increased fecal fat excretion may explain the
observed body weight loss and body fat loss in the
thylakoid-fed mice in these studies, but also in previous
studies where adiposity in mice measured with DEXA
were found to decrease significantly [6].
Other lipase inhibitors like orlistat used for treatment
of obesity increases fecal fat, in humans to 16 g per day,
a level which is three-fold higher than allowed levels.
Such a high excretion of fat may lead to gastrointestinal
adverse events that were also found by the majority in
the treatment group [21]. The excretion of fecal fat may
however be an important mechanism to induce body
weight and body fat loss, as observed by Orlistat treat-
ment [21]. Chitosan with a potential to block fat absorp-
tion fails to induce body weight loss [22] and does not
either cause any increased fecal fat content [23].
Fecal fat excretion may lead to overeating, as observed
in colipase-deficient mice having a massive steatorrhea
[24]. However, we found no compensatory overeating
(Table 1), which suggests other functional properties of
thylakoid membranes to stabilize body weight. Such
properties may be an increased release of satiety hor-
mones like CCK and GLP-1, as observed in rodents [6]
and in humans [25, 26]. An increased release of satiety
hormones suggests a delayed absorption of nutrients
from the intestine during digestion through thylakoid
membranes. In previous publications, we have found no
evidence of increased faecal fat excretion by the addition
of thylakoids despite body weight and fat mass loss, nei-
ther in man [9], nor in rat [7]. The thylakoid enriched
high-fat diet used in mice was the same as previously
used for rat, suggesting a species difference. In rat, the
absence of fat in faeces could be due to a slower passage
of food through the intestine [9], giving the possibility
for an increased intestinal fatty acid oxidation [10] and/
or a more complete fat absorption.
A reduced fat absorption due to thylakoid supplement
as found here, decreased fat mass and also changed the
adipose cell size distribution (ranging between 30–100 μm
in the thylakoid-high-fat fed animals, compared to
50–150 μm in the control high-fat fed animals (Fig. 5).
Indeed, the size of the adipocytes resembled those
measured in mice fed a low-fat diet (Fig. 5). In parallel,
we observed in the thylakoid fed animals observed an
upregulation of PPARγ, its down-stream target FAS,
and of PGC-1γ and LPIN-1, nuclear transcriptional
coactivators of PPARs, which stimulate the differenti-
ation of new adipocyte precursors and promote lipo-
genesis [27]. In our study we could not determine the
activity of the nuclear receptor PPARγ, to support that
an increased protein expression also meant an in-
creased activity. We hypothesize that thylakoid sup-
plementation could stimulate lipid storage in small
cells by recruitment of precursors (hyperplasia), rather
than expanding already large cells (hypertrophia). This
is important since enlarged cells are associated with
inflammation and impaired metabolic homeostasis.
An increased basal lipid storage capacity was observed
in both mesenteric and epididymal adipocytes isolated
from mice fed thylakoids (Fig 4.). Thus, increased PPARγ,
PGC-1α and LPIN-1 expression together with the
Fig. 5 a-b Adipocyte size distribution a in large versus small cell
fraction (defined as above and below the nadir point, marked with
arrow), dotted line represents previous reported cell size distribution
of chow-fed mice (chow control group) [12], here inserted for
comparison. The mean cell size of the cells in the large fraction b
from mice fed HFD vs ThylHFD for two weeks. Bars represent
median and interquartile range. Statistical difference of p < 0.05
was considered significant (**p < 0.01)
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distribution profile, and an increased expression of the en-
zyme FAS which is central for lipid metabolism, support
the hypothesis of an increased recruitment of metabolic-
ally active adipocyte precursors that could explain the
reduced fat mass even with increased lipogenesis. Investi-
gations have identified several natural agonists for PPARγ,
bioactive compounds being plant antioxidants such as
luteolin, quercitin, catechin and resveratrol [28]. Thyla-
koids contain antioxidants in large amounts, like lutein,
karotenoids and zeaxantin. Therefore, we also hypothesize
that these antioxidants may be responsible for an inter-
action with the PPARγ system.
In this study, ThylHFD-fed mice also accumulated less
fat in the liver compared to HFD-fed mice. Earlier stud-
ies have demonstrated reduced levels of triacylglycerol in
the blood by thylakoids [4, 6], but this is the first time
that we observe a reduction of fat accumulation in the
liver. This finding may be of clinical importance, since
NAFLD is a metabolic disorder and a multi-system dis-
ease, strongly associated with obesity, insulin resistance
and type-2 diabetes [29], the incidence of NAFLD in-
creasing at an alarming rate [30]. Due to its effects on
hepatic oxidative capacity, circulating TG and free fatty
acid levels, LPIN-1 has been suggested as a potential
therapeutic target for obesity-related dyslipidaemia and
NAFLD [30]. Possibly, treatment with thylakoids in-
creases LPIN-1 expression in liver similar to adipocytes
that may reduce fat accumulation.
Conclusions
In conclusion we have demonstrated that thylakoids
when given to mice fed a high-fat diet reduce food in-
take while increasing fecal fat excretion without causing
steatorrhea. This led to reduced body weight, fat mass
and liver fat accumulation. Adipocytes were found to be
reduced in size and possibly these correspond to a cell
population that is more insulin sensitive than larger adi-
pocytes. Further studies are needed to find out if there is
a change in fat cell size and increased insulin sensitivity
also in humans.
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for normalization. Western blot images shown in e. Bars represent median and interquartile range. Statistical difference of p < 0.05 was considered
significant (*p < 0.05, **p < 0.01)
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